Objective:To evaluate the efficacy, safety, and economics of ertapenem in the treatment of infectious diseases by means of rapid health technology assessment.Methods:The relevant databases and health technology assessment websites (up to July 31, 2023) were searched to collect the meta-analyses and economic literature on the efficacy, safety, and economics of ertapenem and other antibacterial drugs in the treatment of infectious diseases. The quality of meta-analyses and economic researches were evaluated by a measurement tool to assess systematic reviews and consolidated health economic evaluation reporting standards, respectively. The patients were divided into ertapenem group and control group (using other antibacterial drugs). The outcome indicators of meta-analysis (clinical cure rate, bacterial clearance rate) and the incidence of adverse reactions were compared between the 2 groups. The economic research were cost-effectiveness analysis and cost-consequence analysis. The relevant results were described qualitatively.Results:A total of 13 literature were enrolled, including 7 systematic reviews/meta-analyses (4 of high-quality, 3 of medium quality) and 6 pharmacoeconomics literature (4 of high quality, 2 of medium quality). There were no significant differences on the clinical cure rate and bacterial clearance rate for complex abdominal infection, community-acquired pneumonia, complex skin and appendage infection between the ertapenem group and the control group (all P>0.05). The clinical cure rate of severe diabetic foot infection in the ertapenem group was lower than that in the piperacillin sodium and tazobactam sodium group [91.5% (119/130) vs. 97.2% (139/143), P=0.04]. The bacterial clearance rate of complicated urinary tract infection in the ertapenem group was higher than that in the ceftriaxone group [98.71% (305/309) vs. 95.45% (273/286), P=0.03]. The incidence of adverse reactions (elevated transaminase and alkaline phosphatase or elevated platelet count) in patients with complex abdominal infection in the ertapenem group was higher than that in the control group [8.96% (68/759) vs. 6.49 %(50/771), P<0.05]. The incidence of adverse reactions after ertapenem treatment for complex infections (community-acquired pneumonia, complicated urinary tract infection and complex abdominal infection) was higher than that in ceftriaxone treatment with or without metronidazole group [10.62% (163/1 535) vs. 7.89% (91/1 153), P=0.02]. The incidence of diarrhea in patients with diabetic foot infection in the ertapenem group was lower than that in the piperacillin sodium and tazobactam sodium group [8.14% (24/295) vs. 14.09% (41/291), P=0.02]. It was more cost-effective using ertapenem than using piperacillin sodium and tazobactam sodium, ceftriaxone in treatment of complex abdominal infection, diabetic foot infection, complicated urinary tract infection, community-acquired pneumonia, etc. Conclusions:The efficacy of ertapenem in treatment for complex abdominal infection, community-acquired pneumonia and complex skin and appendage infection are similar to that of commonly used antibiotics in clinic, and the bacterial clearance rate in treatment for complicated urinary tract infection was higher than that of ceftriaxone. There are differences in the incidence of adverse reactions in complex abdominal infection, community-acquired pneumonia, complicated urinary tract infection, and diabetic foot infection between the 2 groups. The use of ertapenem can reduce the cost of drug treatment and has economic advantages.

Objective:To evaluate the efficacy, safety, and economics of ertapenem in the treatment of infectious diseases by means of rapid health technology assessment.Methods:The relevant databases and health technology assessment websites (up to July 31, 2023) were searched to collect the meta-analyses and economic literature on the efficacy, safety, and economics of ertapenem and other antibacterial drugs in the treatment of infectious diseases. The quality of meta-analyses and economic researches were evaluated by a measurement tool to assess systematic reviews and consolidated health economic evaluation reporting standards, respectively. The patients were divided into ertapenem group and control group (using other antibacterial drugs). The outcome indicators of meta-analysis (clinical cure rate, bacterial clearance rate) and the incidence of adverse reactions were compared between the 2 groups. The economic research were cost-effectiveness analysis and cost-consequence analysis. The relevant results were described qualitatively.Results:A total of 13 literature were enrolled, including 7 systematic reviews/meta-analyses (4 of high-quality, 3 of medium quality) and 6 pharmacoeconomics literature (4 of high quality, 2 of medium quality). There were no significant differences on the clinical cure rate and bacterial clearance rate for complex abdominal infection, community-acquired pneumonia, complex skin and appendage infection between the ertapenem group and the control group (all P>0.05). The clinical cure rate of severe diabetic foot infection in the ertapenem group was lower than that in the piperacillin sodium and tazobactam sodium group [91.5% (119/130) vs. 97.2% (139/143), P=0.04]. The bacterial clearance rate of complicated urinary tract infection in the ertapenem group was higher than that in the ceftriaxone group [98.71% (305/309) vs. 95.45% (273/286), P=0.03]. The incidence of adverse reactions (elevated transaminase and alkaline phosphatase or elevated platelet count) in patients with complex abdominal infection in the ertapenem group was higher than that in the control group [8.96% (68/759) vs. 6.49 %(50/771), P<0.05]. The incidence of adverse reactions after ertapenem treatment for complex infections (community-acquired pneumonia, complicated urinary tract infection and complex abdominal infection) was higher than that in ceftriaxone treatment with or without metronidazole group [10.62% (163/1 535) vs. 7.89% (91/1 153), P=0.02]. The incidence of diarrhea in patients with diabetic foot infection in the ertapenem group was lower than that in the piperacillin sodium and tazobactam sodium group [8.14% (24/295) vs. 14.09% (41/291), P=0.02]. It was more cost-effective using ertapenem than using piperacillin sodium and tazobactam sodium, ceftriaxone in treatment of complex abdominal infection, diabetic foot infection, complicated urinary tract infection, community-acquired pneumonia, etc. Conclusions:The efficacy of ertapenem in treatment for complex abdominal infection, community-acquired pneumonia and complex skin and appendage infection are similar to that of commonly used antibiotics in clinic, and the bacterial clearance rate in treatment for complicated urinary tract infection was higher than that of ceftriaxone. There are differences in the incidence of adverse reactions in complex abdominal infection, community-acquired pneumonia, complicated urinary tract infection, and diabetic foot infection between the 2 groups. The use of ertapenem can reduce the cost of drug treatment and has economic advantages.

OBJECTIVE:To systematically evaluate therapeutic efficacy and safety of Yupingfeng powder in adjavant therapy of allergic rhinitis,and to provide evidence-based reference for clinical treatment. METHODS:Retrieved from Wanfang database,VIP,CJFD,CBM,Cochrane Library,EMBase and PubMed,RCTs about Yupingfeng powder combined with chemical medicine (trial group)vs. chemical medicine alone in the treatment of allergic rhinitis were collected. Meta-analysis was conducted by using Rev Man 5.2 statistical software after data extraction and quality evaluation according to Cochrane system evaluation method 5.1.0. RESULTS:A total of 15 RCTs were included,invovling 1366 patients. The results of Meta analysis showed that response rate [OR=3.95,95%CI(2.80,5.58),P<0.001],recurrence rate [OR=0.37,95%CI(0.22,0.63),P<0.001] and the incidence of ADR [OR=0.15,95%CI(0.06,0.35),P<0.001] in trial group were significantly higher than control group,with statistical significance. CONCLUSIONS:Yupingfeng powder in adjuvant therapy of allergic rhinitis show good therapeutic efficacy and can reduce recur-rence rate with good safety.

OBJECTIVE To study the effect of using Beclomethasone Dipropionate (BDP)nasal spray on seasonal perennial allergic rhinitis. METHODS To 100 clinics indeed patients was divided into random for three groups:Cetirizine Hydyrochloeide Tablets cure 30 of set,take orally Cetirizine Hydyrochloeide Tablets 10 mg,everyday once; The BDP nasal spray 30 of set,spraying fog to BDP nasal spray, everyday 2 times,every time two per nostril(or everyday 3-4 times,every time a per nostril),dosage everyday can't over eight(400?g);Cetirizine Hydyrochloeide Tablets add BDP nasal spray to unite to cure 40 of set,using the medicine method together up.Cure time is a 7-14 days,have four times at least with visit the register, distinguish after treatment the 1 hour,the 7 days,the 14 days. Advertise for to carry on the valuation to account the cent to the nose department and a symptom,body of non-nose with observer from the sufferer, according to get a goal how much carry on the curative effect evaluation and covariances to learn the processing. RESULTS Cetirizine Hydyrochloeide Tablets and BDP nasal spray to have no obviously bad reaction towards cure the seasonal allergic rhinitis is all valid. Cetirizine Hydyrochloeide Tablets add BDP nasal spray to unite to cure a curative effect to equal the BDP nasal spray a treatment set but hight in Cetirizine Hydyrochloeide Tablets cure the set,through the x~2 examination,the difference has to statistics to learn the meaning. CONCLUSION Put together the function unite that the antihistamine and glucocorticoid,is the most valid under medical treatment the seasonal allergic rhinitis of method. Ideal treatment medicine is sine can cure the acute reaction symptom, and then cure the late hair reaction symptom.

[Objective] To evaluate the effect of Bushen Yixin Tablet (BYT) on blood pressure (BP) and hemorrheology in rats with hypertension. [Methods] Rat models of hypertension were established by constricting either of the bilateral renal arteries with one clip. Sixty rats were randomly allocated to high - dose BYT group (Group A), low - dose BYT group (Group B), nitrendipine (Group C) and normal saline group (Group D) . Ten rats served as mimic group (Group E) . BP of tail artery was examined in various groups and after a 4 - week treatment, whole blood viscosity and indexes of erythrocyte aggregation (EA) and erythrocyte deformation (ED) were detected. [Results] BP was increased, high- , middle - and low - shear whole blood viscosity and EA index were elevated and ED index was decreased in model rats as compared with those of the normal. After treatment, BP and whole blood viscosity were reduced and ED index was increased in Group A, Group B and Group C, and EA index in Group A was lowered as compared with those in Group D (P